Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a development stage pharmaceutical company that seeks to acquire, develop and commercialize innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved alternatives to current methods of treatment. Specifically, we are developing Northera™ (droxidopa), a novel therapeutic agent, for the treatment of symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure (Parkinson’s disease, or PD, multiple systems atrophy, or MSA, and pure autonomic failure, or PAF), dopamine-?-hydroxylase, or DBH, deficiency and non-diabetic autonomic neuropathy. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.44 |
| Quarterly EPS Est: | -0.06 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.6 |
Data is provided by Zacks Investment Research

